INT213216

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.37
First Reported 2006
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 3
Disease Relevance 2.08
Pain Relevance 0.04

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (PDE5A) signal transduction (PDE5A) cellular_component (PDE5A)
Anatomy Link Frequency
pulmonary artery 2
PDE5A (Homo sapiens)
Pain Link Frequency Relevance Heat
tolerance 14 85.36 High High
Calcium channel 12 34.40 Quite Low
Pain 3 27.76 Quite Low
cva 11 5.12 Low Low
antagonist 9 5.00 Very Low Very Low Very Low
headache 5 5.00 Very Low Very Low Very Low
fibrosis 2 5.00 Very Low Very Low Very Low
cytokine 1 5.00 Very Low Very Low Very Low
Inflammation 1 5.00 Very Low Very Low Very Low
Bioavailability 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Pulmonary Hypertension 236 99.80 Very High Very High Very High
Increased Venous Pressure Under Development 27 98.52 Very High Very High Very High
Hypoxia 13 94.24 High High
Apoptosis 4 93.74 High High
Reprotox - General 2 30 84.00 Quite High
Disease Progression 1 56.64 Quite High
Pressure Volume 2 Under Development 8 30.48 Quite Low
Pain 5 27.76 Quite Low
Disease 19 8.28 Low Low
Interstitial Lung Diseases 3 8.24 Low Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Tadalafil, another PDE5 inhibitor approved for PAH earlier this year, is a once daily medication used at a dose of 40 mg daily.
Positive_regulation (approved) of Gene_expression (approved) of PDE5 associated with pulmonary hypertension
1) Confidence 0.37 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2868348 Disease Relevance 0.66 Pain Relevance 0.04
Many potential targets for therapeutic intervention in PAH have been identified.44 NO formation in pulmonary artery endothelium is needed to promote pulmonary artery vasodilation and inhibition of smooth muscle cell proliferation. 45 The production of cyclic guanosine monophosphate (cGMP) by activation of guanylate cyclase by NO in turn activates protein kinase G (PKG) that decreases pulmonary artery smooth muscle cell calcium and potassium levels leading to pulmonary artery vasodilation, decreased smooth muscle cell proliferation, and increased apoptosis of pulmonary artery smooth muscle cells.31 Patients with PAH have been shown to have both decreased nitric oxide production from the pulmonary artery endothelium and to have increased PDE5 expression in the pulmonary artery smooth muscle cells.46–48 The combined effects of decreased nitric oxide production and increased PDE5 expression ultimately promote pulmonary artery vasoconstriction and increased pulmonary vascular resistance.
Positive_regulation (increased) of Gene_expression (expression) of PDE5 in pulmonary artery associated with pulmonary hypertension, apoptosis and increased venous pressure under development
2) Confidence 0.35 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2868348 Disease Relevance 0.68 Pain Relevance 0
In humans, PDE 5 expression was increased in remodeled pulmonary arteries from patients with idiopathic PAH and familial PAH.
Positive_regulation (increased) of Gene_expression (expression) of PDE 5 associated with pulmonary hypertension
3) Confidence 0.34 Published 2006 Journal Vascular Health and Risk Management Section Body Doc Link PMC1994020 Disease Relevance 0.74 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox